FDA Grants Approval Status for Isoproterenol Hydrochloride Application
The FDA has granted an approval status (AP) for ANDA220299, a generic application for Isoproterenol Hydrochloride submitted by ASPIRO.
Therapeutic Area
Therapeutic area intelligence for Beta-agonist with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.